IRIS
MEGNA, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.330
EU - Europa 3.357
AS - Asia 2.235
AF - Africa 86
SA - Sud America 12
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.032
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.278
DE - Germania 1.478
SG - Singapore 1.040
IT - Italia 978
HK - Hong Kong 574
CN - Cina 396
NL - Olanda 243
IE - Irlanda 146
FI - Finlandia 110
IN - India 101
FR - Francia 92
CI - Costa d'Avorio 78
GB - Regno Unito 68
UA - Ucraina 47
VN - Vietnam 45
CA - Canada 41
RU - Federazione Russa 39
SE - Svezia 39
BG - Bulgaria 23
ES - Italia 22
JP - Giappone 12
AU - Australia 8
ID - Indonesia 8
KR - Corea 8
MX - Messico 8
PL - Polonia 8
IL - Israele 7
RO - Romania 7
AT - Austria 6
CH - Svizzera 6
GR - Grecia 6
TH - Thailandia 6
TR - Turchia 6
BE - Belgio 5
CZ - Repubblica Ceca 5
RS - Serbia 5
AR - Argentina 4
EU - Europa 4
IR - Iran 4
PK - Pakistan 4
TW - Taiwan 4
AL - Albania 3
BD - Bangladesh 3
CO - Colombia 3
EE - Estonia 3
LT - Lituania 3
MY - Malesia 3
NO - Norvegia 3
PH - Filippine 3
PT - Portogallo 3
AM - Armenia 2
BR - Brasile 2
CY - Cipro 2
DK - Danimarca 2
DZ - Algeria 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
MK - Macedonia 2
SA - Arabia Saudita 2
TN - Tunisia 2
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
EC - Ecuador 1
GL - Groenlandia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LV - Lettonia 1
MA - Marocco 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 10.032
Salva come PNG Salva come JPEG
Città #
Singapore 863
Chandler 687
Hong Kong 565
Santa Clara 552
Krefeld 387
Ashburn 348
Amsterdam 224
Napoli 188
Naples 179
Bad Bellingen 171
Millbury 168
Lawrence 146
Boston 145
Des Moines 131
Nanjing 82
Wilmington 63
Beijing 62
Seattle 62
Princeton 58
Dublin 54
Milan 48
Dong Ket 44
Rome 44
Fairfield 42
Houston 38
Lappeenranta 38
Menlo Park 34
Los Angeles 32
Washington 31
Woodbridge 30
Nanchang 28
Kronberg 27
Guangzhou 26
Helsinki 26
Sofia 23
Arezzo 20
Pune 20
Munich 19
Shenyang 19
Ottawa 18
Hebei 17
Council Bluffs 15
Dallas 15
Frankfurt am Main 15
Paris 14
New York 13
Redwood City 13
Boardman 12
Fremont 12
Norwalk 11
Moscow 10
Tianjin 10
Edinburgh 9
Tokyo 9
Changsha 8
Esslingen am Neckar 8
Falls Church 8
Jiaxing 8
Shanghai 8
Xi'an 8
Zhengzhou 8
Ann Arbor 7
Chengdu 7
Chicago 7
Falkenstein 7
Florence 7
Genoa 7
Karlsruhe 7
Madrid 7
Mountain View 7
Turin 7
Valle 7
Wuhan 7
Catania 6
Freiburg im Breisgau 6
Mumbai 6
Nuremberg 6
San Gennaro Vesuviano 6
Abano Terme 5
Abidjan 5
Bhubaneswar 5
Bologna 5
Latina 5
Mexico City 5
New Delhi 5
Sassari 5
Shenzhen 5
Afragola 4
Cagliari 4
Chennai 4
Cosenza 4
Jacksonville 4
Kochi 4
Magenta 4
Monastier di Treviso 4
Mount Compass 4
Qingdao 4
Sacile 4
Sialkot 4
Treviso 4
Totale 6.184
Salva come PNG Salva come JPEG
Nome #
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort 327
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 327
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) 304
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 302
A case of aquagenic wrinkling of the palms 168
Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists 93
An indolent nasal form of primary cutaneous CD8-positive peripheral T-cell lymphoma not otherwise specified successfully treated with local radiation therapy- a new subtype? 86
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications 80
"Active" photoprotection: sunscreens with DNA repair enzymes. A review of the literature 71
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 67
Apremilast efficacy and safety in elderly psoriasis patients over a 48-weeks period 64
A case of the co-existence of subcorneal pustular dermatosis and pyoderma gangrenosum and a review of the literature 59
Generalized Pustular Psoriasis rapidly and successfully treated with Ixekizumab in a Caucasian patient 58
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence 54
Psoriasis in a cohort of patients with common variable immunodeficiency 53
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears 53
Generalized violaceous maculopapular rash and multiple verrucous nodules on the testes: a case of secondary syphilis misdiagnosed as lymphoma 53
Cutaneous leucocytoclastic vasculitis during secukinumab treatment 52
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study 52
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 51
Italian guidelines in diagnosis and treatment of alopecia areata 51
Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment 49
The Role of Thermal Water in Chronic Skin Diseases Management: A Review of the Literature 49
Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist 48
Erythrodermic psoriasis successfully and rapidly treated with brodalumab: report of two cases 48
The effect of the ketogenic diet on Acne: Could it be a therapeutic tool? 47
A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation 47
What's new about atopic dermatitis and sporting activity 46
A case of erythrodermic psoriasis successfully treated with ixekizumab. 46
Immunocytometric analysis of COVID patients: A contribution to personalized therapy? 46
Psoriasis in elderly and non elderly population: clinical and molecular features. 45
The effects of etanercept on replication, proliferation, survival, and apoptosis markers in moderate to severe psoriasis. 44
Adult atopic dermatitis: a review 44
Chronic hand Eczema: Is IL-36á helpful in diagnosis and classification? 44
Anti‐interleukin‐23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice 44
Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role? 44
Aquagenic wrinkling of the palms: a case report and literature review 43
Erythrodermic Pityriasis Rubra Pilaris treatment: two case reports and literature review 43
Coronavirus disease and dermatology: current and future challenges 43
Psoriasis in Children: a Review. 42
Melanoma frequency among symmetrical Spitzoid-looking lesions: a retrospective study 42
Acne prevalence in 9 to 14-year-old old patients attending pediatric ambulatory clinics in Italy 42
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 42
Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI) 41
Systemic treatment for psoriasis and malignancies: A real risk? 41
Secukinumab Drug Survival in Patients with Psoriasis: A multicenter, real-world, retrospective study 41
Giant nodular melanoma of the nose in a 78‐year old female refusing complete excision 41
Biologics for psoriasis in COVID-19 era: what do we know? 41
Is there any association between psoriasis, psoriatic arthritis and thyroid autoimmunity? 41
Cutaneus sarcoidosis small-fiber neuropathy resembling leprosy: a case report 40
QuantiFERON TB‐gold conversion rate among psoriasis patients under biologics: a 9‐year retrospective study 40
Tralokinumab in elderly atopic dermatitis 39
Psoriasis in melanoma patients: a prospective pilot study. 39
Guselkumab for the treatment of psoriasis 39
Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis 39
Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1‐year period 39
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II 39
Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. 38
Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia. 37
L'avvento degli inibitori delle proteasi nella terapia dell'infezione da epatite C: Reazioni avverse dermatologiche 37
Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation 37
Psoriasis and high school students: an educational approach 37
Infantile Acute Generalized Pustular Psoriasis: A Case Report 37
Primary bilateral malignant melanoma of the lower limbs 37
Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. 37
Letter to the editor submitted in response to "psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab" 37
Intralesional Methotrexate for the Treatment of Keratoacanthoma: The Neapolitan Experience 37
Alopecia universalis improvement following risankizumab in a psoriasis patient 37
Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center 37
Appearances may be deceiving 36
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study 36
Psoriasis Features in Patients with Inflammatory Bowel Disease 36
Dermoscopic patterns of intradermal naevi 36
Impact of current anti-psoriatic systemic treatments on male and female fertility: what the endocrinologist needs to know 36
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period 36
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 35
A case of Paediatric Acrodermatitis Continua of Hallopeau successfully treated with adalimumab biosimilar 35
Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient 35
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 35
Skin diseases and visual arts 34
Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study 34
Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future 34
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data 34
Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period 34
16-year real-life study on the prevalence of mycoses in a paediatric population 34
New frontiers in personalized medicine in psoriasis 33
Patient-physician relationship in patients with psoriasis. 33
Insulin Resistance and Skin Diseases 33
Psoriatic arthritis and psoriasis: differential diagnosis 33
Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents. 33
Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment 33
A case of juvenile amyopathic dermatomyositis 33
The role of histological presentation in erythroderma 33
Rowell Syndrome: A Diagnostic Challenge 33
Itraconazole‐induced photodistributed erythema multiforme 33
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection 33
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas 32
Photodynamic Therapy and Skin Appendage Disorders: A Review 32
Pyoderma gangrenosum successfully treated with topical tacrolimus 32
Chronic inducible urticarias in children 32
Totale 5.469
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.585
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.585
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020219 0 0 0 0 0 0 16 3 18 64 75 43
2020/2021651 28 33 33 38 77 30 28 161 94 27 43 59
2021/20221.301 22 32 21 44 39 52 30 92 155 103 219 492
2022/20232.027 234 168 66 93 211 201 72 207 311 254 165 45
2023/20243.132 101 238 225 143 111 213 58 187 1.287 73 344 152
2024/20252.716 468 590 81 85 266 587 639 0 0 0 0 0
Totale 10.629